Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The added value of H2 antagonists in premedication regimens during paclitaxel treatment.
Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PMLA, Boere IA, Jager A, Mathijssen RHJ, van Leeuwen RWF. Cox JM, et al. Among authors: van leeuwen rwf, van doorn l, van den bemt pmla. Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG. Eskens FA, et al. Among authors: van doorn l. Br J Cancer. 2008 Jan 15;98(1):80-5. doi: 10.1038/sj.bjc.6604108. Epub 2007 Nov 20. Br J Cancer. 2008. PMID: 18026190 Free PMC article. Clinical Trial.
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH. de Graan AJ, et al. Among authors: van der bol jm, van doorn l, van der holt b. Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645049
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V. Eskens FA, et al. Among authors: van doorn l, van der gaast a. Br J Cancer. 2014 Apr 29;110(9):2170-7. doi: 10.1038/bjc.2014.137. Epub 2014 Apr 8. Br J Cancer. 2014. PMID: 24714750 Free PMC article. Clinical Trial.
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.
Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group. Verheijen RB, et al. Among authors: van doorn l. Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. doi: 10.1158/1078-0432.CCR-16-1255. Epub 2016 Jul 28. Clin Cancer Res. 2016. PMID: 27470967
Capecitabine and the Risk of Fingerprint Loss.
van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. van Doorn L, et al. JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. JAMA Oncol. 2017. PMID: 27560202 No abstract available.
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP. Beukhof CM, et al. Among authors: van doorn l, van kemenade fj, van heerebeek r. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2922-2929. doi: 10.1210/jc.2016-4025. J Clin Endocrinol Metab. 2017. PMID: 28575418
286 results